


# *Un centro integral de investigación del cáncer en Red*



INSTITUTO DE BIOLOGÍA MOLECULAR Y CELULAR DEL  
CÁNCER - CENTRO DE INVESTIGACIÓN DEL CÁNCER  
**IBMCC-CIC (CSIC – USAL)**  
*Salamanca (Spain)*



# IBMCC-CIC MISSION AND VISION


The IBMCC-CIC is a joint enterprise between the Spanish Council for Scientific Research (CSIC) and the University of Salamanca. It is also a recognised Health Centre from the Castilla-León Health System



[www.cicancer.org](http://www.cicancer.org)

**IBMCC:** Instituto de Biología Molecular y Celular del Cáncer

Centro Sociosanitario de Castilla y León



# CARACTERÍSTICAS DEL CIC

## INVESTIGACIÓN de EXCELENCIA

### INTEGRACIÓN DE INVESTIGACIÓN


- básica
- clínica
- aplicada

Búsqueda de riqueza y bienestar social

### CALIDAD

### COMPETITIVIDAD


Objetivo:  
EFICACIA en investigación oncológica



# CARACTERÍSTICAS DEL CIC

**INVESTIGACIÓN PUNTERA basada en los comprehensive cancer centers**


Un CCC es un modelo restrictivo, hay **menos de cuarenta reconocidos en EEUU**, y su requisito fundamental es que debe desarrollar investigación puntera -evaluada externamente- de tres tipos: básica, clínica y aplicada. Ha demostrado ser el más eficiente a la hora de obtener los mejores resultados prácticos en investigación oncológica.




# *The IBMCC-CIC intends to follow the model of the USA Comprehensive Cancer Centers*


## GOALS:

- ✓ To create an environment of research excellence that could compete in equal terms with other national and international cancer centres.
- ✓ To promote a synergistic cooperation among basic, clinical, and translational laboratories.
- ✓ To conduct a multifaceted study of the tumorigenic process at the basic, translational, and clinical level.
- ✓ To develop new diagnostic and prognostic tools of application to cancer patients.
- ✓ To put in motion technical and diagnostic facilities that favour cancer diagnostics, prognostics and the development of new anti-tumoral therapies and treatments.
- ✓ To promote interactions with other national and international cancer centres as well as with the biopharmaceutical industry.
- ✓ To train specialized personnel at the technical, graduate, and postdoctoral level in molecular, translational, and clinical oncology.





# ORGANIZATION: MANAGEMENT







# ORGANIZATIONAL CHART





# ORGANIZATION OF RESEARCH UNITS





# BASIC RESEARCH TEAMS



**Avelino Bueno**

*Cell cycle analysis. Control of mitosis and checkpoint response in eukaryotic cells*



**Xosé Bustelo**

*Small GTPases and cancer . Rho/Rac mediated signalling*



**Sergio Moreno**

*Cell cycle analysis. Cell division and cell differentiation.*

*Oncopharmacology. Drug target discovery*



**Atanasio Pandiella**

*Kinases in oncology. Signalling by receptor tyrosine kinases*

*Oncopharmacology. Novel drugs in haematological malignancies*



**Alberto M. Pendás**

*Animal models in cancer. Chromosome instability and cancer*




**Eugenio Santos**

*Small GTPases and cancer . Ras mediated signalling*



**José María Pereda**

*Structural biology*



# TRANSLATIONAL RESEARCH TEAMS



**Rogelio Glez. Sarmiento**

*Clinical and molecular analysis of solid tumors and hereditary cancer*



**Pedro A. Lazo**

*Kinases in oncology. Signalling by serine-threonine kinases*

*Oncopharmacology. Ser-Thr kinase targets in oncology*



**Faustino Mollinedo**

*Cell death and cancer. Lipid rafts and death receptors*

*Oncopharmacology. Drug discovery and mechanisms of action*




**Isidro Sánchez García**

*Cancer stem cells and cell therapy*



**Felipe X. Pimentel**

*Cell death and cancer. Atypical cell death pathways*



# CLINICAL RESEARCH TEAMS



**Juan Jesús Cruz**

*Clinical and molecular analysis of solid tumors and hereditary cancer.  
Clinical Oncology*



**Enrique de Álava**

*Molecular Pathology . Tumor Bank*



**Alberto Gómez Alonso**

*Clinical and molecular analysis of solid tumors and hereditary cancer.  
Surgery*



**Alberto Orfao**


*Immunology and cancer. Molecular Diagnostic & Citometry*




**Jesús San Miguel**

*Oncohematology.*

*Oncopharmacology. Novel drugs in haematological malignancies*



# CIC EMERGENT RESEARCHERS (ISCIII-Miguel Servet Researchers)



**Azucena Esparís Ogando**  
*Novel targets in breast cancer.*




**Mercedes Garayoa Berrueta**  
*Bone marrow microenvironment and bone lesions in multiple myeloma*



**Andrés García Montero**  
*Proteomic characterisation of chronic lymphoproliferative T and NK syndromes.*





# CIC EMERGENT RESEARCHERS

## (Ramón y Cajal Program, PCD)



**Julia Almeida**

*Phenotypic, molecular and functional characterization of the tumor hematological TNK mature cells.*



**Mercedes Dosil**

*Control of ribosomal biogenesis. Coupling between ribosomal biogenesis and signalling / oncogenic pathways.*



**Maria Sacristan**

*Regulatory mechanisms in mitotic exit in human cells.*

**Alberto Fdez Medarde**


*Analysis of the functional specificity of guanine nucleotide exchangers for Ras, Grf1 and Grf2.*




**Carmen Guerrero**

*Study of the functional role of C3G in signal transduction and its possible implication in chronic myeloid leukaemia.*







# SOCIO-SANITARY SERVICE UNITS



**Genomics and Proteomics Unit, Bioinformatics**  
Directors: Drs. X. R. Bustelo J. De Las Rivas




**Molecular, Cellular, and Cytogenetic Services**  
Director: Drs. J. San Miguel and A. Orfao




**Early Diagnosis Program and Genetic Counseling**  
Director: Drs. R. Sarmiento and J.J. Cruz



**Traslational Oncopharmacology**  
Director: Dr. Atanasio Pandiella




**Tumour Bank and Molecular Pathology Units**  
Director: Dr. E. de Álava



**National DNA Bank**  
Director: Drs. A. Orfao and E. de Álava




**Graduate Program, CME, Scientific diffusion, Information to patients, advocacy E.Santos**



# RESEARCH LINES: SCIENTIFIC NETWORKING ESTABLISHED



NATIONAL  
COORDINATION



Genoma España G

TUMOR BANK

GENOM&PROT

NEW THERAPIES

TUMOR REGISTRY

MOL. DIAGNOSTICS


ANIMAL MODELS

BIOINFORMATICS

EDUCATION & TRAINING




**bancoadn**



# RED TEMATICA DE INVESTIGACION COOPERATIVA EN CANCER (RTICC)

2007-2011



- **82 Grupos regulares**
- **21 Grupos clínicos asistenciales**



- 4 Líneas verticales
- 13 CC.AA.

Coordinada desde el CIC de Salamanca

- 6 Programas horizontales
- - 5 M € / año



# *Financiación*





CiC



# Financiación

FUNDING, IBMCC - 1999/2004





# Financiación



## Financiación

**Nacional:** MICINN, ISCIII

**Regional:** CYL

**Nacional privada:** AECC, Ramón Areces, otras.

**Europea:** Programa Marco

**USA:** privada (MMRF, IMF), NIH

**Industria:** Nacional e Internacional



**CiC**

